CLLKF Stock Chart & Stats
$1.74
$0.03(1.84%)
At close: 4:00 PM EDT
$1.74
$0.03(1.84%)
Day’s Range― - ―
52-Week Range$1.38 - $2.74
Previous CloseN/A
Volume500.00
Average Volume (3M)146.00
Market Cap
$147.87M
Enterprise Value$1.20K
Total Cash (Recent Filing)$627.60M
Total Debt (Recent Filing)$266.40M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Nov 11, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.89
Shares Outstanding69,074,900
10 Day Avg. Volume13
30 Day Avg. Volume146
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.85
Price to Sales (P/S)0.99
P/FCF Ratio26.97
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)$169.17M
Bulls Say, Bears Say
Bulls Say
Material Margin Expansion And Operating LeverageGross-margin expansion from 44% to 59%, alongside a 21-point adjusted EBITDA-margin improvement and lower operating expenses, indicates meaningful operating leverage. If sustained, the efficiency program and improved product mix can strengthen earnings conversion and provide a more durable path toward profitability.
Long-term Contracted Revenue OpportunityThe Scienion agreement adds substantial multi-year contracted value and provides an important commercial anchor for the business. Although licensing revenue is recognized at a point in time, the associated supply relationship can deepen customer ties and improve revenue visibility over the medium term.
Recurring Consumables Growth And Product InnovationConsumables growth supports the recurring portion of BICO’s model because customers continue purchasing materials after instrument adoption. Continued benchtop momentum and new workflow products can expand the installed-base opportunity, improve mix, and reinforce BICO’s relevance in cell-based research.
Bears Say
Deeply Negative ProfitabilityThe company has not yet converted its revenue base into sustainable earnings, with deeply negative net and operating profitability and materially worse annual results in 2025. Persistent losses can limit internally funded investment, weaken resilience, and increase the risk of future dilution or additional financing.
Weak And Deteriorating Cash GenerationSlightly negative free cash flow indicates that BICO currently has limited self-funding capacity, even though operating cash flow remains marginally positive. The deterioration from prior years reduces flexibility to finance product development, absorb execution setbacks, or pursue growth without relying more heavily on its balance sheet.
Project Execution And Automation Demand RiskExecution problems in the U.S. project business create a durable risk to revenue timing, margins, and customer confidence because multi-year projects can produce delayed and lumpy recognition. Longer purchasing cycles for large automation systems may further postpone backlog conversion and complicate operating planning.
BICO Group AB Class B News
CLLKF FAQ
What was BICO Group AB Class B’s price range in the past 12 months?
BICO Group AB Class B lowest stock price was $1.38 and its highest was $2.74 in the past 12 months.
What is BICO Group AB Class B’s market cap?
BICO Group AB Class B’s market cap is $147.87M.
When is BICO Group AB Class B’s upcoming earnings report date?
BICO Group AB Class B’s upcoming earnings report date is Nov 11, 2026 which is in 56 days.
How were BICO Group AB Class B’s earnings last quarter?
BICO Group AB Class B released its earnings results on Aug 19, 2026. The company reported -$0.052 earnings per share for the quarter, beating the consensus estimate of -$0.073 by $0.021.
Is BICO Group AB Class B overvalued?
According to Wall Street analysts BICO Group AB Class B’s price is currently Overvalued.
Does BICO Group AB Class B pay dividends?
BICO Group AB Class B does not currently pay dividends.
What is BICO Group AB Class B’s EPS estimate?
BICO Group AB Class B’s EPS estimate is -0.02.
How many shares outstanding does BICO Group AB Class B have?
BICO Group AB Class B has 69,074,900 shares outstanding.
What happened to BICO Group AB Class B’s price movement after its last earnings report?
BICO Group AB Class B reported an EPS of -$0.052 in its last earnings report, beating expectations of -$0.073. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BICO Group AB Class B?
Currently, no hedge funds are holding shares in CLLKF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BICO Group AB Class B
BICO Group AB (publ) is a global bio-convergence enterprise, extending its operations across North America, Europe, Asia, and other international markets. Its business is segmented into two primary divisions: Laboratory Solutions and Bioautomation. The Laboratory Solutions division equips researchers with advanced tools like 3D bioprinters, hybrid microscopes, and instruments for single-cell dispensing and liquid handling. It also supplies essential consumables such as bioinks, reagents, microscope lenses, and specialized software, alongside 3D reconstructed human tissues crucial for regulatory testing. Furthermore, this segment provides specialized services in 3D cell culture, tissue imaging, multiplex imaging, and digital pathology, primarily benefiting pharmaceutical and biotechnology firms. Conversely, the Bioautomation segment caters to industrial clients with precision dispensing and biosensor technologies, while also delivering diagnostic automation and sophisticated robotics solutions to the medical and diagnostics sectors. Beyond these segments, BICO Group's comprehensive portfolio includes solutions for tissue engineering, multi-omics, cell line development, and diagnostics, contributing to a robust industrial ecosystem. Its principal clientele spans the medical, pharmaceutical, and cosmetic industries. Originally established in 2016 as Cellink AB (publ), the company adopted its current name, BICO Group AB (publ), in August 2021. Its headquarters are located in Gothenburg, Sweden.
CLLKF Company Deck
CLLKF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call combined meaningful operational and financial improvements (strong product launches, a large long-term license/supply agreement, substantial gross margin expansion, improved adjusted EBITDA margin, reductions in operating expenses and a stronger balance sheet) with persistent operational and market headwinds (project execution issues in the U.S. project business, negative operating cash flow driven by working capital movements, soft North American/academic end markets and longer sales cycles for large automation projects). Progress on commercialization and profitability is clear, but execution risk in project-based automation and short-term cash-flow/working-capital pressure leave mixed near-term visibility.View all CLLKF earnings summariesTechnical Analysis
Vitrolife AB
―
BONESUPPORT HOLDING AB
―
CellaVision AB
―
Xvivo Perfusion AB
―
OssDsign AB
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.56% Other Institutional Investors
95.13% Public Companies and
Individual Investors